Jessie R. Groothuis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jessie R. Groothuis has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Nishida
NeonatalDivision, Tokyo Women’s Medical College Maternal and PerinatalCenter, Tokyo, Japan
1 shared publicationIan Mitchell
Alberta’s Childrens Hospital
1 shared publicationJuergen Seidenberg
Elisabeth Kinderkrankenhaus
1 shared publicationMarques Valido
Maternidade Alfredo da Costa, Serviço de Pediatria
1 shared publicationMartin Cihar
University Hospital Motol
1 shared publicationMichal Csader
University Children’s Hospital
1 shared publication
Latest Publications
- 1 July 2003
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 22 (7) , 414-417
Safety of Palivizumab in Preterm Infants 29 to 32 Weeks' Gestational Age Without Chronic Lung Disease to Prevent Serious Respiratory Syncytial Virus Infection
Respiratory syncytial virus is an important cause of hospitalization in preterm infants. Palivizumab, a humanized monoclonal antibody against the respiratory syncytial virus fusion protein, is currently the only licensed product in Europe available for prophylaxis of respiratory syncytial virus lower respiratory tract infection. This study was conducted to obtain additional European data on the safety of palivizumab in preterm infants 29–32 weeks' gestational age without chronic lung disease. Subjects less than 6 months old were enrolled between October 2000 and April 2001. Demographic information was obtained and physical examination was performed at enrollment. Subjects received 15 mg/kg palivizumab intramuscularly every 30 days for the duration of the respiratory syncytial virus season. Subjects hospitalized for respiratory illness were tested for respiratory syncytial virus infection with respiratory syncytial virus rapid antigen tests. At monthly visits, interim history for adverse events/respiratory illness and physical exam was performed. A total of 285 subjects were enrolled from 35 centers in 18 countries. The mean (±SD) gestational age was 30.8±1.1 weeks, the mean birth weight 1.5±0.4 kg, and 56% were 5%) were rhinitis, increased cough, fever, pharyngitis, bronchiolitis, and diarrhea. Only six subjects reported adverse events that were considered possibly related to palivizumab. No deaths were reported. Twenty subjects were hospitalized during the study; six of these were respiratory syncytial virus positive. Palivizumab is safe and well tolerated in preterm infants 29–32 weeks' gestation without chronic lung disease.
- 1 July 2003
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 22 (7) , 414-417
Safety of Palivizumab in Preterm Infants 29 to 32 Weeks' Gestational Age Without Chronic Lung Disease to Prevent Serious Respiratory Syncytial Virus Infection
Respiratory syncytial virus is an important cause of hospitalization in preterm infants. Palivizumab, a humanized monoclonal antibody against the respiratory syncytial virus fusion protein, is currently the only licensed product in Europe available for prophylaxis of respiratory syncytial virus lower respiratory tract infection. This study was conducted to obtain additional European data on the safety of palivizumab in preterm infants 29–32 weeks' gestational age without chronic lung disease. Subjects less than 6 months old were enrolled between October 2000 and April 2001. Demographic information was obtained and physical examination was performed at enrollment. Subjects received 15 mg/kg palivizumab intramuscularly every 30 days for the duration of the respiratory syncytial virus season. Subjects hospitalized for respiratory illness were tested for respiratory syncytial virus infection with respiratory syncytial virus rapid antigen tests. At monthly visits, interim history for adverse events/respiratory illness and physical exam was performed. A total of 285 subjects were enrolled from 35 centers in 18 countries. The mean (±SD) gestational age was 30.8±1.1 weeks, the mean birth weight 1.5±0.4 kg, and 56% were 5%) were rhinitis, increased cough, fever, pharyngitis, bronchiolitis, and diarrhea. Only six subjects reported adverse events that were considered possibly related to palivizumab. No deaths were reported. Twenty subjects were hospitalized during the study; six of these were respiratory syncytial virus positive. Palivizumab is safe and well tolerated in preterm infants 29–32 weeks' gestation without chronic lung disease.
- 1 January 2003
- Published by Springer Nature in Drug Safety
- Vol. 26 (4) , 283-291
Evaluation of the Safety of Palivizumab in the Second Season of Exposure in Young Children at Risk for Severe Respiratory Syncytial Virus Infection
Background: Palivizumab reduces respiratory syncytial virus (RSV) hospitalisations in high-risk infants. Those with severe bronchopulmonary dysplasia may require two seasons of prophylaxis. There is...
- 1 January 2003
- Published by Springer Nature in Drug Safety
- Vol. 26 (4) , 283-291
Evaluation of the Safety of Palivizumab in the Second Season of Exposure in Young Children at Risk for Severe Respiratory Syncytial Virus Infection
Background: Palivizumab reduces respiratory syncytial virus (RSV) hospitalisations in high-risk infants. Those with severe bronchopulmonary dysplasia may require two seasons of prophylaxis. There is...
- 6 June 2002
- Published by Wiley in Pediatrics International
- Vol. 44 (3) , 235-241
Prevention of respiratory syncytial virus infections in high‐risk infantsby monoclonal antibody (palivizumab)
Respiratory syncytial virus (RSV) is a major viral pathogen whichcauses serious respiratory illness in infants and children worldwide.Palivizumab (Synagis) is an anti‐RSV monoclonal antibody administeredintramuscularly for the prevention of severe RSV respiratory diseasein high‐risk infants and young children. The IMpact‐RSV trial, thepivotal multicenter, randomized, placebo‐controlled trial performedin the USA, Canada and the United Kingdom demonstrated an overall55% reduction in hospitalization rate due to RSV infection inpreterm infants (≤ 35 weeks gestation)with and without chronic lung disease (CLD). Subgroup analysis in prematureinfants without CLD revealed an even greater reduction in RSV hospitalizationrates (78%). Adverse events were infrequent and did notdiffer between placebo and palivizumab groups. Injection site reactionswere infrequent and mild; no differences were observed between palivizumaband placebo subjects. Palivizumab does not interfere with administrationof other pediatric vaccines. Comprehensive parent education programsregarding prevention of infection, avoidance of risk factors forinfection, careful adherence to infection control policies, andrecognition of early symptoms of RSV infection remain important componentsof RSV prevention strategies. In light of the lack of effectivevaccines for this serious health risk, palivizumab offers the onlyoption for prophylaxis against RSV disease in high‐risk infants.
- 6 June 2002
- Published by Wiley in Pediatrics International
- Vol. 44 (3) , 235-241
Prevention of respiratory syncytial virus infections in high‐risk infantsby monoclonal antibody (palivizumab)
Respiratory syncytial virus (RSV) is a major viral pathogen whichcauses serious respiratory illness in infants and children worldwide.Palivizumab (Synagis) is an anti‐RSV monoclonal antibody administeredintramuscularly for the prevention of severe RSV respiratory diseasein high‐risk infants and young children. The IMpact‐RSV trial, thepivotal multicenter, randomized, placebo‐controlled trial performedin the USA, Canada and the United Kingdom demonstrated an overall55% reduction in hospitalization rate due to RSV infection inpreterm infants (≤ 35 weeks gestation)with and without chronic lung disease (CLD). Subgroup analysis in prematureinfants without CLD revealed an even greater reduction in RSV hospitalizationrates (78%). Adverse events were infrequent and did notdiffer between placebo and palivizumab groups. Injection site reactionswere infrequent and mild; no differences were observed between palivizumaband placebo subjects. Palivizumab does not interfere with administrationof other pediatric vaccines. Comprehensive parent education programsregarding prevention of infection, avoidance of risk factors forinfection, careful adherence to infection control policies, andrecognition of early symptoms of RSV infection remain important componentsof RSV prevention strategies. In light of the lack of effectivevaccines for this serious health risk, palivizumab offers the onlyoption for prophylaxis against RSV disease in high‐risk infants.